Carolina Hospital
Targeted therapy in Poland costs from $15,000 to $30,000 on average. Total prices depend on the cancer type, specific drug protocols, and clinic location. In the US, similar procedures cost around $40,000 on average. Patients save around 44% compared to US rates. Treatment typically includes oncologist consultations and personalized molecular diagnostics.
Bookimed Expert Insight: Poland offers a high-value balance of Western medical standards and lower logistical costs. Clinics like Carolina Hospital maintain ISO 9001:2015 certification while serving international patient volumes. Choosing major hubs like Warsaw ensures access to the latest molecular testing. This data-driven approach allows for more precise drug selection. It often results in better outcomes without the premium prices found in Germany.
Why choose Poland for targeted therapy?
Access advanced Targeted therapy solutions in trusted clinics .
| Poland | Turkey | Austria | |
| Targeted therapy | from $15,000 | from $1,000 | from $12,000 |
| Lutetium-177 therapy | from $15,000 | from $8,800 | from $35,000 |
| Actinium-225 Therapy | from $30,000 | from $22,955 | from $55,000 |
| Oncothermia | - | from $450 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Targeted therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Targeted therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Targeted therapy journey.
Day 1: Arrival
Day 2: Pre-Operation Stage
Day 3: Targeted Therapy
Day 4: Post-Operation Stage
Week 1-2: Rehabilitation
Please note that each patient"s case is individual and can vary.
What patients like:
What patients don't like:
As the leading global medical tourism platform, Bookimed.com takes responsibility before its clients - both patients and medical centers in Poland. All the information provided on the website is grounded in research, foresight, and expertise and meets high interest related to the product and follows:
We form our listings of clinics and doctors with strict regulations of our smart automatic ranking system. The system is based on real Bookimed patient rates to provide the most objective and transparent information about clinics and medical services there in Poland.
Our experienced data scientist collects data daily, monitors and optimizes the ranking system using machine learning and artificial intelligence to ensure that the ranking system is up-to-date and provides accurate results.
We collect the opinions of Bookimed clients only after getting medical experience with the clinic in Poland - so everyone on the platform can trust the facility they choose. We strive to make the content on our platform as useful as possible and ensure the freedom to express critical opinions. Thus, we publish positive and negative reviews, aiming at being a source for informed decision-making for our future clients.
On Bookimed.com, you may find choice and convenience to find the best medical solutions from top medical services providers in Poland just in one place, and often at competitive prices. Making sure to deliver the freshest information, the clinic’s representatives update doctors’ CVs, clinics’ capacities, before-after pictures, prices, packages, and specials by themselves shortly. You may meet the clinic’s representative and check the date of updated content at every clinic’s page to make sure of its trustworthiness.
Our blog and supportive pieces are created by professional authors with at least 3-year experience in medical writing and edited by medical specialists with relevant clinical and research expertise - all carefully recruited to the team. We strive to enhance patient access to health information in Poland, making it expert but easy to understand. All pieces follow the Bookimed’s Editorial Guidelines.
We are made of people and for people in Poland - and that"s our core value. That"s why all the data presented on the platform is collected, edited, reviewed, and updated regularly by our patients, our partner clinics, and our team, including the Bookimed Medical Advisory Board, which consists of the world-renowned doctors with value expertise over 20 years of practice, and a positive reputation. Learn more about us and our mission.
In case you find any mistake or have any questions on the information presented on Bookimed.com in Poland, please feel free to contact us at marketing@bookimed.com.
Dr. Andrzej Komor is an orthopaedic surgeon with extensive experience. He treats conditions of the ankle, foot, knee, and shoulder. He uses advanced stem cell therapies to repair joint damage and improve recovery for his patients.
Dr. Komor has been practicing since 1993. He has completed internships in Israel, the USA, Spain, and Austria, gaining valuable international experience. In 2000, he received the EFORT Traveling Fellowship, a respected European award in orthopaedics. He worked in Spain from 2006 to 2013, further building his clinical skills.
Written by Anna Shchur
When considering Targeted therapy, it’s important to understand the different techniques and which is best suited for you. Here’s a concise comparison of popular options:
Lutetium-177 therapy is a targeted radiotherapy utilizing the Lutetium-177 radioisotope to treat certain cancers effectively.
Targeted therapy is precision medicine that uses drugs to attack specific genetic mutations or proteins in cancer cells. Unlike traditional chemotherapy, which kills all rapidly dividing cells, targeted therapy focuses on unique molecular markers, sparing healthy tissue and causing fewer systemic side effects.
Bookimed Expert Insight: While basic targeted drugs are widely available, specialized nuclear medicine like Lutetium-177 or Actinium-225 is concentrated in advanced Polish centers. These radio-targeted therapies specifically treat prostate cancer or neuroendocrine tumors. Accessing these advanced subtypes in Poland can save up to 44% compared to average US costs of $40,000.
Patient Consensus: Patients value the convenience of oral pills but emphasize the need for early genetic testing. Many recommend navigating reimbursement options early, as access to the newest drugs can sometimes face administrative delays.
Eligibility for targeted therapy in Poland depends on molecular confirmation of specific genetic mutations. A multidisciplinary tumor board makes the final decision based on biomarkers like EGFR, ALK, or HER2. Patients must meet clinical criteria within National Health Fund (NFZ) drug programs to receive high-cost treatments.
Bookimed Expert Insight: While public NFZ programs are standard, they often involve a 4-6 week wait. Patients can accelerate this by opting for private NGS panels at specialized centers. This speeds up the qualification process before official drug program enrollment.
Patient Consensus: Patients emphasize the need to apply for drug programs immediately after diagnosis. Advocates suggest using compassionate-use schemes if NFZ funding is initially denied but mutations are present.
Polish oncology centers primarily treat non-small cell lung cancer, breast cancer, and colorectal cancer with targeted therapy. High-priority treatments also include prostate cancer and hematological malignancies. These clinics utilize molecular diagnostics to identify specific genetic markers like EGFR, ALK, and HER2 before starting treatment.
Bookimed Expert Insight: While Poland has 86 specialized centers, diagnostic speed is the biggest differentiator for success. National health fund wait times for genetic testing can reach 3 months. Patients often bypass this by choosing private Next-Generation Sequencing (NGS) panels in Warsaw centers. This allows them to start targeted drugs several weeks earlier than the standard public track.
Patient Consensus: Success depends heavily on early molecular profiling. Patients recommend insisting on an NGS panel at diagnosis to ensure access to the most effective targeted drugs.
Targeted therapy causes side effects like skin rashes, diarrhea, and fatigue by affecting specific proteins. Management involves proactive dermatology referrals, anti-diarrheal medications, and continuous cardiac monitoring. Polish clinics typically employ multidisciplinary teams to manage these symptoms using specialized supportive care protocols during active treatment cycles.
Bookimed Expert Insight: Data shows that side effects typically peak between weeks 2 and 4. Patients who coordinate supportive care with specialists from day 1 report significantly better quality of life. High-volume centers in Warsaw often integrate dermatology and cardiology into the initial oncology plan to prevent treatment interruptions.
Patient Consensus: Many survivors describe the fatigue as crushing and recommend adapting work schedules early. They emphasize that reporting even minor skin changes immediately prevents painful blistering and avoids the need for treatment breaks.
Targeted therapy duration in Poland ranges from 6 months for early-stage cancers to indefinite use for metastatic conditions. Treatment for HER2-positive breast cancer typically lasts 1 year. Patients with advanced lung cancer or melanoma often continue therapy as long as the disease remains stable and manageable.
Bookimed Expert Insight: Data from Polish oncology centers shows a shift toward long-term maintenance. Patients on HER2-specific drugs require cardiac echoes every 6 months lifelong. This differs from chemotherapy where monitoring often decreases after 5 years. In Poland, the NFZ system mandates these specific heart-safety checks indefinitely.
Patient Consensus: Many patients emphasize that resistance can emerge suddenly after years of stability. They recommend staying consistent with quarterly scans even when feeling perfectly healthy.
Polish public health insurance (NFZ) covers targeted therapy only through specific drug programs (programy lekowe) for patients meeting strict clinical and genetic criteria. While public care is free, many patients choose private oncology centers to avoid delays in genetic testing and drug approval queues.
Bookimed Expert Insight: Data suggests a strategic hybrid approach is most effective for international and local patients. Starting with private diagnostics and genetic testing in Warsaw clinics often saves three to six weeks. This acceleration allows patients to enter NFZ programs much faster than through the standard public route.
Patient Consensus: Many patients find that paying privately for initial testing is a vital investment. This small upfront cost often makes the difference between immediate treatment and a lengthy wait for public approval.
International patients find modern targeted therapy with English support at private Polish oncology centers like Maria Sklodowska-Curie National Research Institute and European Health Centre Otwock. These facilities provide specialized international departments, English-speaking coordinators, and advanced molecular diagnostics to create personalized cancer treatment plans.
Bookimed Expert Insight: While public university hospitals offer high clinical standards, private facilities in Warsaw significantly reduce wait times for targeted drugs. Our data shows these private centers often accept English medical records without official translation. This can save patients up to 7 days in the diagnostic phase.
Patient Consensus: Patients recommend contacting international desks via email before traveling to confirm specific drug availability. Many suggest budgeting for pathology re-tests as Polish oncologists frequently re-verify external NGS reports locally.